Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [<29 and 29-32...
שמור ב:
| הוצא לאור ב: | Salud Pública de México |
|---|---|
| Principais autores: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Instituto Nacional de Salud Pública
2012
|
| נושאים: | |
| גישה מקוונת: | https://www.redalyc.org/articulo.oa?id=10623032007 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|